Syneos Health Announces Secondary Offering of Common Stock
MORRISVILLE, N.C., Dec. 01, 2020 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company”…
News
Micron Medical Hosting Key Opinion Leader Webinar on Protect PNS: A Percutaneous Wireless Micro-Neurostimulation Technology for Overactive Bladder December 9 at 11am EST
BOCA RATON, Fla., Dec. 01, 2020 (GLOBE NEWSWIRE) — Micron Medical (“Micron” or “the Company”),…
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or…
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated…
Transactions in connection with share buyback program
Company announcement no. 49 – 201 December 2020 Transactions in connection with share buyback program…
Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first…
Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021…
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”),…
FDA approves Xolair® (omalizumab) for adults with nasal polyps
Xolair is the first biologic for the treatment of nasal polyps that targets and blocks…